Contribution: Industrial Research Assistance Program – Contributions to Firms
Virica Biotech Inc.
$304,720.00
UKRI Biomanufacturing - 10100745 - Viral Enhancers - Development of small molecule formulations for enhanced production of AAV
FY 2024-25 · 2024-05-01
Summary
As part of the international consortium project "Viral Enhancers - Development of small molecule formulations for enhanced production of AAV", this project will focus on developing and demonstrating at scale small molecule formulation(s) which increase the yield of next-generation gene therapies. Development of such technologies will enable faster clinical and commercial development of life saving technologies while simultaneously improving patient access through reduction of cost per dose.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Ottawa|Ottawa, Ontario, Canada
Recipient Type
For-profit organization
Business Number
721336089
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2024-05-01 | 2024-25 | $304,720.00 |
| 2 | 2024-05-01 | 2024-25 | $304,720.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 91 jours.
Agreement End Date
2025-11-30
Agreement Number
1019804
Agreement Start Date
2024-05-01
Agreement Title
UKRI Biomanufacturing - 10100745 - Viral Enhancers - Development of small molecule formulations for enhanced production of AAV
Agreement Title (French)
UKRI Biomanufacturing - 10100745—Viral Enhancers— Développement de formulations de petites molécules pour améliorer la production d’AAV
Agreement Type
Contribution
Agreement Value
$304,720.00
Amendment Date
2025-09-04
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
As part of the international consortium project "Viral Enhancers - Development of small molecule formulations for enhanced production of AAV", this project will focus on developing and demonstrating at scale small molecule formulation(s) which increase the yield of next-generation gene therapies. Development of such technologies will enable faster clinical and commercial development of life saving technologies while simultaneously improving patient access through reduction of cost per dose.
Description (French)
Dans le cadre du projet de consortium international Viral Enhancers — Development of small molecule formulations for enhanced production of AAV, ce projet se concentrera sur le développement et la démonstration à l’échelle d’une ou de plusieurs formulations de petites molécules qui augmentent le rendement des thérapies géniques de la prochaine génération. La mise au point de ces technologies permettra d’accélérer le développement clinique et commercial de technologies qui sauvent des vies, tout en améliorant l’accès des patients grâce à la réduction du coût par dose.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Ottawa Centre
Federal Riding (French)
Ottawa-Centre
Federal Riding Number
35075
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
721336089
Recipient City
Ottawa|Ottawa
Recipient Country
CA
Recipient Legal Name
Virica Biotech Inc.
Recipient Operating Name
Virica Biotech
Recipient Postal Code
K1Z 5N4
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2024-2025-Q1-1019804
